Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs (Nasdaq: VRAX) presented research data on T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting in Davos, Switzerland. The study demonstrated that repeated stimulation of peripheral blood mononuclear cells with SARS-CoV-2 and CMV peptide pools increases the expression of exhaustion markers in CD4⁺ and CD8⁺ T-Cells.
The research showed that T-Cell exhaustion correlates with reduced cytokine production, particularly pro-inflammatory cytokines, leading to impaired immune functionality. Preliminary data from the ViraxImmune™ PAIS assay revealed significant differences in cytokine levels between PAIS patients and healthy controls.
The company has initiated clinical validation studies to evaluate their T-Cell-based diagnostic's performance in assessing the relationship between T-Cell dysfunction and symptoms like chronic fatigue and cognitive impairment in conditions such as long COVID, ME/CFS, and chronic Lyme disease.
Virax Biolabs (Nasdaq: VRAX) ha presentato dati di ricerca sulla disfunzione delle cellule T nei sindromi post-infezione acuta (PAIS) durante il World Immune Regulation Meeting a Davos, Svizzera. Lo studio ha dimostrato che la stimolazione ripetuta delle cellule mononucleari del sangue periferico con pool di peptidi di SARS-CoV-2 e CMV aumenta l'espressione dei marcatori di esaurimento nelle cellule T CD4⁺ e CD8⁺.
La ricerca ha mostrato che l'esaurimento delle cellule T è correlato a una riduzione della produzione di citochine, in particolare delle citochine pro-infiammatorie, portando a una funzionalità immunitaria compromessa. Dati preliminari dal ViraxImmune™ PAIS assay hanno rivelato differenze significative nei livelli di citochine tra pazienti con PAIS e controlli sani.
L'azienda ha avviato studi di validazione clinica per valutare le prestazioni del loro diagnostico basato sulle cellule T nel valutare la relazione tra disfunzione delle cellule T e sintomi come affaticamento cronico e compromissione cognitiva in condizioni come long COVID, ME/CFS e malattia di Lyme cronica.
Virax Biolabs (Nasdaq: VRAX) presentó datos de investigación sobre la disfunción de células T en síndromes post-infección aguda (PAIS) en el World Immune Regulation Meeting en Davos, Suiza. El estudio demostró que la estimulación repetida de células mononucleares de sangre periférica con grupos de péptidos de SARS-CoV-2 y CMV aumenta la expresión de marcadores de agotamiento en células T CD4⁺ y CD8⁺.
La investigación mostró que el agotamiento de células T se correlaciona con una disminución en la producción de citoquinas, particularmente citoquinas pro-inflamatorias, lo que lleva a una funcionalidad inmunológica comprometida. Datos preliminares del ViraxImmune™ PAIS assay revelaron diferencias significativas en los niveles de citoquinas entre pacientes con PAIS y controles sanos.
La empresa ha iniciado estudios de validación clínica para evaluar el rendimiento de su diagnóstico basado en células T en la evaluación de la relación entre la disfunción de células T y síntomas como fatiga crónica y deterioro cognitivo en condiciones como long COVID, ME/CFS y enfermedad de Lyme crónica.
Virax Biolabs (Nasdaq: VRAX)는 스위스 다보스에서 열린 World Immune Regulation Meeting에서 급성 감염 후 증후군(PAIS)에서 T-세포 기능 장애에 대한 연구 데이터를 발표했습니다. 이 연구는 SARS-CoV-2 및 CMV 펩타이드 풀로 말초 혈액 단핵세포를 반복적으로 자극하면 CD4⁺ 및 CD8⁺ T-세포에서 탈진 마커의 발현이 증가한다는 것을 보여주었습니다.
연구 결과, T-세포의 탈진은 특히 염증성 사이토카인의 생산 감소와 상관관계가 있으며, 이는 면역 기능 저하로 이어집니다. ViraxImmune™ PAIS assay의 초기 데이터는 PAIS 환자와 건강한 대조군 간의 사이토카인 수준에서 유의미한 차이를 나타냈습니다.
회사는 T-세포 기반 진단의 성능을 평가하기 위해 임상 검증 연구를 시작하여 T-세포 기능 장애와 만성 피로 및 인지 장애와 같은 증상 간의 관계를 평가하고 있습니다. 이러한 증상은 롱 COVID, ME/CFS 및 만성 라임병과 같은 상태에서 나타납니다.
Virax Biolabs (Nasdaq: VRAX) a présenté des données de recherche sur la dysfonction des cellules T dans les syndromes post-infection aiguë (PAIS) lors de la World Immune Regulation Meeting à Davos, en Suisse. L'étude a démontré que la stimulation répétée des cellules mononucléaires du sang périphérique avec des pools de peptides de SARS-CoV-2 et de CMV augmente l'expression des marqueurs d'épuisement dans les cellules T CD4⁺ et CD8⁺.
La recherche a montré que l'épuisement des cellules T est corrélé à une production réduite de cytokines, en particulier des cytokines pro-inflammatoires, ce qui entraîne une fonctionnalité immunitaire altérée. Les données préliminaires de l'ViraxImmune™ PAIS assay ont révélé des différences significatives dans les niveaux de cytokines entre les patients PAIS et les témoins sains.
L'entreprise a lancé des études de validation clinique pour évaluer la performance de son diagnostic basé sur les cellules T dans l'évaluation de la relation entre la dysfonction des cellules T et des symptômes tels que la fatigue chronique et les troubles cognitifs dans des conditions telles que le long COVID, le ME/CFS et la maladie de Lyme chronique.
Virax Biolabs (Nasdaq: VRAX) präsentierte Forschungsdaten zur T-Zell-Dysfunktion bei postakuten Infektionssyndromen (PAIS) auf dem World Immune Regulation Meeting in Davos, Schweiz. Die Studie zeigte, dass die wiederholte Stimulation von peripheren mononukleären Blutzellen mit SARS-CoV-2- und CMV-Peptid-Pools die Expression von Erschöpfungsmarkern in CD4⁺- und CD8⁺-T-Zellen erhöht.
Die Forschung ergab, dass T-Zell-Erschöpfung mit einer verringerten Zytokinproduktion korreliert, insbesondere mit proinflammatorischen Zytokinen, was zu einer beeinträchtigten Immunfunktion führt. Vorläufige Daten aus dem ViraxImmune™ PAIS assay zeigten signifikante Unterschiede in den Zytokinspiegeln zwischen PAIS-Patienten und gesunden Kontrollen.
Das Unternehmen hat klinische Validierungsstudien initiiert, um die Leistung ihres T-Zell-basierten Diagnosetests zur Bewertung der Beziehung zwischen T-Zell-Dysfunktion und Symptomen wie chronischer Müdigkeit und kognitiven Beeinträchtigungen bei Zuständen wie Long COVID, ME/CFS und chronischer Lyme-Borreliose zu bewerten.
- Development of ViraxImmune™ PAIS assay showing promising preliminary results
- Initiation of clinical validation studies for T-Cell-based diagnostic
- Scientific validation through presentation at prestigious WIRM conference
- Research still in preliminary stages without completed clinical validation
- No immediate revenue generation potential mentioned
PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion. Chronic antigen stimulation following a chronic infection can cause upregulation of T-Cell exhaustion markers. Data demonstrated that repeated stimulation of peripheral blood mononuclear cells (PBMCs) with SARS-CoV-2 and CMV peptide pools increases the proportion of CD4⁺ and CD8⁺ T-Cells expressing exhaustion markers PD-1, LAG-3, TIGIT, TIM-3, and CD39 with each stimulation cycle. T-Cell exhaustion is well documented to correlate with reduced cytokine production, particularly of pro-inflammatory cytokines, resulting in impaired immune functionality. Additionally, preliminary data from the ViraxImmune™ PAIS assay showed significant changes in the levels of a number of cytokines investigated in patients with PAIS compared to healthy controls.
"This data highlights the critical role of T-Cell exhaustion in immune dysfunction, particularly in PAIS conditions like long COVID, ME/CFS and chronic Lyme disease," said Nigel McCracken, Chief Operating Officer at Virax Biolabs. "In conjunction, we have initiated a number of clinical validation studies to evaluate the performance our T-Cell-based diagnostic in assessing the link between T-Cell dysfunction and symptoms of chronic fatigue and cognitive impairment."
A link to the poster presentation can be found here on the Virax Biolabs corporate website.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Caution Concerning Forward-looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "intends," "potential," or "hopes" or the negative of these or similar terms. Forward-looking statements are only predictions. The forward-looking events discussed in this press release, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; successful development of our intended products; our ability to gain regulatory approval to offer our products or services in our targeted markets; our ability to keep pace with new technology and changing market needs; protection of our intellectual property rights; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2024. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-presents-data-on-t-cell-dysfunction-in-post-acute-infection-syndromes-at-the-19th-world-immune-regulation-meeting-302400809.html
SOURCE Virax Biolabs
FAQ
What did Virax Biolabs (VRAX) present at the 2025 World Immune Regulation Meeting?
What are the key findings of Virax Biolabs' PAIS research?
What conditions is Virax Biolabs' T-Cell research targeting?
What clinical studies is VRAX currently conducting for their T-Cell diagnostic?
